These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15645013)

  • 1. Open-channel blockers of the NMDA receptor complex.
    Albensi BC; Ilkanich E
    Drug News Perspect; 2004 Nov; 17(9):557-62. PubMed ID: 15645013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
    Lipton SA
    Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
    Lipton SA
    NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers.
    Hu LY; Guo J; Magar SS; Fischer JB; Burke-Howie KJ; Durant GJ
    J Med Chem; 1997 Dec; 40(26):4281-9. PubMed ID: 9435897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia.
    Müller WE; Mutschler E; Riederer P
    Pharmacopsychiatry; 1995 Jul; 28(4):113-24. PubMed ID: 7491365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?
    Albensi BC; Igoechi C; Janigro D; Ilkanich E
    Am J Alzheimers Dis Other Demen; 2004; 19(5):269-74. PubMed ID: 15553982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
    Rogawski MA; Wenk GL
    CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
    Lipton SA
    Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trialkylglycines: a new family of compounds with in vivo neuroprotective activity.
    Sánchez-Pérez AM; Montoliu C; Felipo V
    CNS Drug Rev; 2003; 9(3):263-74. PubMed ID: 14530798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
    Kornhuber J; Weller M
    Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block.
    Dravid SM; Erreger K; Yuan H; Nicholson K; Le P; Lyuboslavsky P; Almonte A; Murray E; Mosely C; Barber J; French A; Balster R; Murray TF; Traynelis SF
    J Physiol; 2007 May; 581(Pt 1):107-28. PubMed ID: 17303642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMDA/NR2B selective antagonists in the treatment of ischemic brain injury.
    Wang CX; Shuaib A
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):143-51. PubMed ID: 15857299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
    Lipton SA; Gu Z; Nakamura T
    Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo.
    Parsons CG; Quack G; Bresink I; Baran L; Przegalinski E; Kostowski W; Krzascik P; Hartmann S; Danysz W
    Neuropharmacology; 1995 Oct; 34(10):1239-58. PubMed ID: 8570022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide.
    Lipton SA
    Trends Neurosci; 1993 Dec; 16(12):527-32. PubMed ID: 7509524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices.
    Rammes G; Hasenjäger A; Sroka-Saidi K; Deussing JM; Parsons CG
    Neuropharmacology; 2011 May; 60(6):982-90. PubMed ID: 21310164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.